

SYNGAP1: Why are we still missing this diagnosis in ASD?

Written by The Life Science Feed Editorial Team · Published 20 October 2026 · Edited by Mara Voss

Despite growing recognition of SYNGAP1 as a significant genetic contributor to intellectual disability and autism spectrum disorder (ASD), this diagnosis is still frequently missed in clinical practice. This oversight delays targeted management and family counseling, highlighting the critical need for increased awareness and advanced diagnostic approaches.

KEY TAKEAWAYS

- **The Pivot:** Whole-exome sequencing is increasingly crucial for diagnosing neurodevelopmental disorders like ASD when initial investigations are inconclusive, as demonstrated by the identification of a de novo SYNGAP1 mutation.
- **The Data:** A de novo frameshift mutation in the SYNGAP1 gene was identified via whole-exome sequencing.
- **The Action:** Consider advanced genetic testing, specifically whole-exome sequencing, in children presenting with unexplained developmental delays or ASD, especially when standard evaluations yield limited insights.

Background on *SYNGAP1* and ASD

The SYNGAP1 gene provides instructions for making a protein called SynGAP, which is crucial for the development and function of synapses in the brain. These synapses are essential for communication between neurons, affecting learning, memory, and overall cognitive function. Mutations in SYNGAP1 are increasingly recognized as a cause of intellectual disability and autism spectrum disorder.^{2,3,4} Clinically, SYNGAP1-related disorders often manifest with a range of symptoms including developmental delays, seizures, and behavioral issues. Identifying these mutations is pivotal, as it allows for more informed clinical management and family counseling.

The Case Presentation

The case report details the journey of a child presenting with significant developmental delays and features indicative of ASD. The child exhibited impaired social interaction, repetitive behaviors, and delayed speech development. Standard clinical assessments and initial investigations provided limited insight into the underlying etiology. The patient's complex presentation prompted clinicians to pursue more advanced diagnostic avenues.

The Diagnostic Process

The diagnostic journey involved a series of evaluations, including neurological assessments, behavioral evaluations, and metabolic screenings. These initial tests failed to pinpoint a specific cause for the child's condition. Given the lack of

a definitive diagnosis, the clinical team opted for whole-exome sequencing to explore potential genetic contributions. This decision underscores the increasing reliance on advanced genetic testing in complex and undiagnosed cases of neurodevelopmental disorders.

Genetic Findings

Whole-exome sequencing revealed a de novo frameshift mutation in the SYNGAP1 gene. This mutation was not present in either parent, indicating that it arose spontaneously in the child. Frameshift mutations disrupt the normal reading frame of the gene, leading to a nonfunctional protein. This finding provided a definitive genetic diagnosis, explaining the child's combined presentation of intellectual disability and ASD. The identification of this mutation allowed for more targeted management and counseling for the family.

Comparison to Guidelines

Current guidelines from the American Academy of Pediatrics (AAP) recommend considering genetic testing, including chromosomal microarray analysis and exome sequencing, in children with unexplained developmental delays or ASD. This case supports and reinforces these recommendations, demonstrating the clinical utility of advanced genetic testing in unraveling complex neurodevelopmental disorders. While the AAP guidelines don't specifically highlight SYNGAP1, the growing body of evidence linking it to ASD strengthens the rationale for including it in broader genetic screening panels for neurodevelopmental disorders.^{1,2,3,4} It also challenges clinicians to remain updated on the expanding list of genes associated with ASD.³

Study Limitations

As a case report, the generalizability of these findings is limited. The study focuses on a single patient with a specific SYNGAP1 mutation, and the clinical presentation may vary in other individuals with different mutations in the same gene. Furthermore, the study does not explore the functional consequences of the identified mutation in detail, which could provide additional insights into the underlying pathophysiology. Larger cohort studies are needed to fully characterize the phenotypic spectrum associated with SYNGAP1 mutations and to assess the prevalence of these mutations in individuals with ASD and intellectual disability.

Molecular Mechanism

The SynGAP protein plays a critical role in synaptic plasticity, which is essential for learning and memory. The de novo frameshift mutation identified in this case leads to a truncated, nonfunctional SynGAP protein. This loss of function disrupts synaptic signaling pathways, impairing neuronal communication and contributing to the development of intellectual disability and ASD. Specifically, SynGAP regulates the Ras/MAPK signaling pathway, which is involved in neuronal growth and differentiation. Dysregulation of this pathway due to SynGAP deficiency can lead to abnormal brain development and cognitive dysfunction. Understanding these molecular mechanisms is crucial for developing targeted therapies for SYNGAP1-related disorders. Further research is needed to elucidate the precise role of SynGAP in synaptic function and to identify potential therapeutic targets for these devastating conditions.

CLINICAL IMPLICATIONS

The most striking consequence of missing a SYNGAP1 diagnosis is the lost opportunity for targeted intervention and family support. Identifying this specific genetic cause moves us beyond a generic ASD diagnosis, allowing clinicians to anticipate specific comorbidities and tailor management strategies. This precision medicine approach is increasingly vital in neurodevelopmental disorders, offering a clearer path for patients and their families.

For clinicians, this case underscores the necessity of considering advanced genetic testing, like whole-exome sequencing, earlier in the diagnostic process for unexplained developmental delays or ASD. The American Academy of Pediatrics guidelines already recommend genetic testing in these scenarios. While SYNGAP1 is not yet explicitly highlighted, its growing recognition demands that specialists stay updated on emerging genetic associations to ensure comprehensive diagnostic workups.

The pharmaceutical industry should take note of the increasing identification of specific genetic drivers for ASD. This trend opens avenues for developing targeted therapies that address the underlying molecular mechanisms, rather than just managing symptoms. As our understanding of genes like SYNGAP1 expands, so too does the potential for innovative treatments that could significantly improve patient outcomes.

Finally, for patients and their families, a definitive genetic diagnosis provides invaluable clarity. It offers an explanation for their child's challenges, informs prognosis, and connects them to specific support groups and research initiatives. This knowledge empowers families, guiding them toward more effective management and offering hope for future therapeutic advancements.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Varghese M, Keshav N, Jacot-Descombes S, et al. Autism spectrum disorder: neuropathology and animal models. *Acta Neuropathol.* 2017;134(4):537-566. doi:10.1007/s00401-017-1736-4
2. Vlastkamp DRM, Shaw BJ, Burgess R, et al. SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy. *Neurology.* 2019;92(2):e96-e107. doi:10.1212/WNL.0000000000006729
3. Zhang Y, Tang R, Hu ZM, et al. Key Synaptic Pathology in Autism Spectrum Disorder: Genetic Mechanisms and Recent Advances. *J Integr Neurosci.* 2024;23(10):184. doi:10.31083/j.jin2310184
4. Libé-Philippot B, Iwata R, Recupero AJ, et al. Synaptic neoteny of human cortical neurons requires species-specific balancing of SRGAP2-SYNGAP1 cross-inhibition. *Neuron.* 2024;112(21):3602-3617.e9. doi:10.1016/j.neuron.2024.08.021

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com